30 closest matches · ranked by relevance
Microcystic Lymphatic Malformation
Primary: Incidence of Treatment-Emergent Adverse Events — 9; 2; 6; 2 participants
Lymphatic Malformations
Primary: Number of Participants With Clinical Success at 1 to 6 Months Post-Therapy as Assessed by Imaging — 57 Participants
Lymphatic Malformations · Lymphatic Diseases
Primary: Change in Lesion Volume of the Test Medication as Evaluated by MRI Examination. — 5.89; -8.54; -0.642 percentage of volume
Lymphangioma
Primary: Change in Volume of Lymphatic Malformation — 3.7; -4.3; -1.0; -31.7 percentage of volume change
Vascular Malformations · Vascular Malformation Peripheral · Venous Malformation
Primary: Volume Difference of Malformation to Baseline (no Compression) While Wearing Compression Stockings Class I and II Determined by MRI — 16.38; 23.7 ml
Secondary Lymphedema
Primary: Assessing a Change in Bioimpedance Spectroscopy (BIS) — 1.3; 1.8 Change of score on a scale
Breast Neoplasm · Lymphedema
Primary: Lymphoedema Volume at the Level of the Arm/ Hand — 1.228; 1.249; 1.218; 1.175 Inter-limb ratio
Lipedema
Primary: Change in Weight From Baseline — 0.340 kilograms — p=0.473
Lymph Node Dissection · Lymphoedema · Lymphocoele
Primary: Postoperative Draining Time — 31; 32 days
Breast Cancer · Axillary Lymph Node Dissection
Primary: Number and Prevalence of Metastases of Blue Nodes in the ALND Specimen (Nodes Draining the Breast). — 0 participants
Breast Cancer · Lymphedema
Primary: Arm Volume — 1.48; 1.58 cm^3
Head and Neck Neoplasms · Head and Neck Lymphedema · Head and Neck Cancer
Primary: Lymph Movement Measured by ICG Lymphography. — 5; 5; 0; 0 Participants
Melanoma · Sentinel Node
Primary: Equivalence of ICG and Real Time Lymphangiography to technetium99 and Blue Dye in Localizing Sentinel Nodes — 1.87 number of sentinel nodes per patient
Lymphangioleiomyomatosis · Lymphangiomyomas · Pleural Effusions
Primary: Number of Participants With a Reduction in Total Tumor Volume of at Least 20%. — 0 Participants
Lymphedema
Primary: LDex Change- — 28.0; 17.8; 22.2 LDex
Lipedema · Lipolymphedema
Primary: Change in Circumferential Measurements Over Time — -0.5; -1.0; -1.3; -2.0 cm
Hemangioma
Primary: MRI/MRA of Head/Neck/Chest. — 357 participants
Breast Cancer · Leptomeningeal Metastasis
Primary: Total Number of Participants With Leptomeningeal Metastasis Detected (ER Status) — 3; 1 Participants
Breast Cancer · Melanoma
Primary: Concordance of Blue Dye and Lymphoseek — 1.0000 Proportion of Lymph Nodes
Breast Cancer With Chronic Lymphedema
Primary: Lymphedema as Measured at Baseline and at 6 Weeks — 4.74; 4.82; 4.29; 4.76 cm
Lymphedema · Edema
Primary: Change in Limb Volume — -15; -202 mL
Recurrent Melanoma
Primary: Sentinel Lymph Nodes (SLN) Mapping — 25; 25; 25; 4 Sentinel lymph nodes
Lymphangioleiomyomatosis
Primary: Changes in Forced Expiratory Volume in One-second (FEV1) Slope in Milliliters Per Month — 1; -12 milliliters per month — p=<0.001
Lymphedema
Primary: Part 1: Count of Participants Able to Complete Ketoprofen Treatment — 50 Participants
Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Primary: Objective Responses in Patients With MALT Lymphoma Presenting With Measureable Disease — 25; 20; 1 Participants
Lymphedema
Primary: Change in Volume Ipsilateral Lymphedema in Arm — -161.0; -372.8 mL — p=0.0658
Pleural Diseases · Pleural Neoplasms
Primary: Malignant Pleural Infiltration Identification — 12; 27; 9; 4 Participants — p=0.023
Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Extranodal Marginal Zone Lymphoma
Primary: Relapse-free Survival (RFS) — 83 months
Cancer
Primary: Percentage of Agreement Between the Detection of SLNs — 69.7 percentage complete agreement
Breast Cancer
Primary: Agreement of Labeling Between Isosulfan Blue (IS-BLUE) and Indocyanine Green (IC-GREEN) — 8 Participants